Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

By Lauren Pelley, CBC News, RCI Provinces taking different approaches, many Canadians may be paying out of pocket Respiratory syncytial virus, or RSV (new window), isn’t always top of mind during the ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

PHILADELPHIA - GSK plc (LSE/NYSE: GSK)宣布了一项3期临床试验的积极结果,表明AREXVY和SHINGRIX疫苗联合接种与分开接种一样有效。这项针对50岁及以上成年人的研究显示,当呼吸道合胞病毒(RSV)疫苗AREXVY和带状疱疹疫苗SHINGRIX(两者均使用AS01佐剂)一起接种时,免疫反应不劣于分开接种。 该试验的结果计划提交给同行评审的科学出版物和FDA ...